These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 35788363)

  • 1. Risk factors for denosumab discontinuation in patients with postmenopausal osteoporosis.
    Hattori K; Takahashi N; Kojima T; Imagama S
    Mod Rheumatol; 2023 Jul; 33(4):843-850. PubMed ID: 35788363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severe Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: 9 Clinical Cases Report.
    Lamy O; Gonzalez-Rodriguez E; Stoll D; Hans D; Aubry-Rozier B
    J Clin Endocrinol Metab; 2017 Feb; 102(2):354-358. PubMed ID: 27732330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of follow-up raloxifene therapy after denosumab discontinuation in postmenopausal women.
    Ha J; Kim J; Jeong C; Lim Y; Kim MK; Kwon HS; Song KH; Kang MI; Baek KH
    Osteoporos Int; 2022 Jul; 33(7):1591-1599. PubMed ID: 35376989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Denosumab treatment lapses, discontinuation, and off-treatment fracture risk: A retrospective study of patients with osteoporosis in a real-world clinical setting.
    Cruchelow KR; Peter ME; Chakrabarti A; Gipson HM; Gregory WT; DeClercq J; Choi L; Tanner SB
    Bone; 2023 Dec; 177():116925. PubMed ID: 37797711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medication-taking behaviour in Bulgarian women with postmenopausal osteoporosis treated with denosumab or monthly oral bisphosphonates.
    Petranova T; Boyanov M; Shinkov A; Petkova R; Intorcia M; Psachoulia E
    Arch Osteoporos; 2017 Dec; 13(1):1. PubMed ID: 29264666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study.
    Papapoulos S; Lippuner K; Roux C; Lin CJ; Kendler DL; Lewiecki EM; Brandi ML; Czerwiński E; Franek E; Lakatos P; Mautalen C; Minisola S; Reginster JY; Jensen S; Daizadeh NS; Wang A; Gavin M; Libanati C; Wagman RB; Bone HG
    Osteoporos Int; 2015 Dec; 26(12):2773-83. PubMed ID: 26202488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple Vertebral Fractures After Denosumab Discontinuation: FREEDOM and FREEDOM Extension Trials Additional Post Hoc Analyses.
    Cosman F; Huang S; McDermott M; Cummings SR
    J Bone Miner Res; 2022 Nov; 37(11):2112-2120. PubMed ID: 36088628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of denosumab on trabecular bone score in postmenopausal women with osteoporosis.
    McClung MR; Lippuner K; Brandi ML; Zanchetta JR; Bone HG; Chapurlat R; Hans D; Wang A; Zapalowski C; Libanati C
    Osteoporos Int; 2017 Oct; 28(10):2967-2973. PubMed ID: 28748386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistence at 24 months with denosumab among postmenopausal women with osteoporosis: results of a prospective cohort study.
    Silverman SL; Siris E; Belazi D; Recknor C; Papaioannou A; Brown JP; Gold DT; Lewiecki EM; Quinn G; Balasubramanian A; Yue S; Stolshek B; Kendler DL
    Arch Osteoporos; 2018 Aug; 13(1):85. PubMed ID: 30088189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension.
    Bone HG; Wagman RB; Brandi ML; Brown JP; Chapurlat R; Cummings SR; Czerwiński E; Fahrleitner-Pammer A; Kendler DL; Lippuner K; Reginster JY; Roux C; Malouf J; Bradley MN; Daizadeh NS; Wang A; Dakin P; Pannacciulli N; Dempster DW; Papapoulos S
    Lancet Diabetes Endocrinol; 2017 Jul; 5(7):513-523. PubMed ID: 28546097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors for vertebral fractures and bone loss after denosumab discontinuation: A real-world observational study.
    Everts-Graber J; Reichenbach S; Gahl B; Ziswiler HR; Studer U; Lehmann T
    Bone; 2021 Mar; 144():115830. PubMed ID: 33359006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maintenance of bone resorption markers in the low premenopausal range during the year following denosumab discontinuation is associated to bone density preservation. The ReoLaus study.
    Liebich G; Lamy O; Aubry-Rozier B; Gonzalez-Rodriguez E
    Bone; 2023 Jul; 172():116764. PubMed ID: 37062514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension.
    Miyauchi A; Dinavahi RV; Crittenden DB; Yang W; Maddox JC; Hamaya E; Nakamura Y; Libanati C; Grauer A; Shimauchi J
    Arch Osteoporos; 2019 Jun; 14(1):59. PubMed ID: 31168657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suboptimal medication adherence may favor the progression of vertebral fractures in women with post-menopausal osteoporosis treated with denosumab.
    Betella N; Biamonte E; Matarazzo C; Piccini S; Olivetti R; Cellini M; Lania AG; Mazziotti G
    Minerva Endocrinol; 2020 Sep; 45(3):165-171. PubMed ID: 32186164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporosis in Canada.
    Chau D; Becker DL; Coombes ME; Ioannidis G; Adachi JD; Goeree R
    J Med Econ; 2012; 15 Suppl 1():3-14. PubMed ID: 23035625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Single Infusion of Zoledronate in Postmenopausal Women Following Denosumab Discontinuation Results in Partial Conservation of Bone Mass Gains.
    Everts-Graber J; Reichenbach S; Ziswiler HR; Studer U; Lehmann T
    J Bone Miner Res; 2020 Jul; 35(7):1207-1215. PubMed ID: 31991007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study.
    Hadji P; Papaioannou N; Gielen E; Feudjo Tepie M; Zhang E; Frieling I; Geusens P; Makras P; Resch H; Möller G; Kalouche-Khalil L; Fahrleitner-Pammer A
    Osteoporos Int; 2015 Oct; 26(10):2479-89. PubMed ID: 26018090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are drug holidays a safe option in treatment of osteoporosis? - Insights from an in silico mechanistic PK-PD model of denosumab treatment of postmenopausal osteoporosis.
    Martínez-Reina J; Calvo-Gallego JL; Pivonka P
    J Mech Behav Biomed Mater; 2021 Jan; 113():104140. PubMed ID: 33080564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship Between Bone Mineral Density and Risk of Vertebral Fractures with Denosumab Treatment in Japanese Postmenopausal Women and Men with Osteoporosis.
    Okubo N; Matsui S; Matsumoto T; Sugimoto T; Hosoi T; Osakabe T; Watanabe K; Takami H; Shiraki M; Nakamura T
    Calcif Tissue Int; 2020 Dec; 107(6):559-566. PubMed ID: 32839843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.
    Bone HG; Bolognese MA; Yuen CK; Kendler DL; Miller PD; Yang YC; Grazette L; San Martin J; Gallagher JC
    J Clin Endocrinol Metab; 2011 Apr; 96(4):972-80. PubMed ID: 21289258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.